Alkermes withdraws EU megestrol application
This article was originally published in Scrip
Executive Summary
Alkermes Pharma Ireland has withdrawn its EU approval application for the cachexia treatment megestrol. The decision was made "as a consequence of portfolio prioritisation", the company said in its official letter to the EMA.